whatshot

TGTX   $35.07  1.51% Market Closed After Close 35.5 1.23%

TG Therapeutics Inc
show_chart Advanced Chart of TGTX
Last Events:

2023-08-09 Signal in Stochastic changed from bearish recovery to bearish weakening. The stochastic indicator is in the oversold territory and it grows. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-06 Trend pattern changed from нисходящий клин to сужающийся канал.

2023-08-06 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: exit from the overbought zone.

2023-08-05 Signal in Stochastic changed from bullish reversal to bearish recovery. The stochastic indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: main and signal line crossing.

2023-08-04 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: exit from the overbought zone.

2023-08-03 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: main and signal line crossing.

2023-08-03 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: exit from the overbought zone.

2023-08-03 Trend changed from flat and up to linear up.

Current temperature: 12.60
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 8
Target Price Mean 38.13
Mean unverified/preliminary 38.13 / 38.13
Target Price Low / High 9.00 / 55.00
Median / STD DEV 42.50 / 15.34
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy ActivelyBuy None
rsi Sell ActivelyBuy None
macd None None None
stoch None None None
ma20 Buy ActivelyBuy None
ma50 None None None
ma100 Buy ActivelyBuy None
Candlestick PatternNov. 14, 2024 Dark Clouds Cover - is a candlestick pattern whereby a black candlestick opens above a white candlesticks close and below its midpoint.Considered to be a bearish reversal pattern.
ISIN US88322Q1085
ceo Mr. Michael S. Weiss Esq.
Website https://www.tgtherapeutics.com
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.